Premium
COMBINATION OF IBRUTINIB WITH RITUXIMAB (IR) IS HIGHLY EFFECTIVE IN PREVIOUSLY UNTREATED ELDERLY (>65 YEARS) PATIENTS (PTS) WITH MANTLE CELL LYMPHOMA (MCL) – PHASE II TRIAL
Author(s) -
Jain P.,
Romaguera J.,
Nomie K.,
Zhang S.,
Wang L.,
Oriabure O.,
WagnerBartak N.,
Zhang L.,
Hagemeister F.,
Samaniego F.,
Westin J.,
Ju Lee H.,
Nastoupil L.,
Iyer S.,
Parmar S.,
Ok C.,
KanagalShamanna R.,
Chen W.,
Thirumurthi S.,
Santos D.,
Badillo M.,
Fayad L.,
Neelapu S.,
Fowler N.,
Wang M.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.11_2629
Subject(s) - medicine , rituximab , mantle cell lymphoma , ibrutinib , gastroenterology , phases of clinical research , progressive disease , regimen , surgery , lymphoma , clinical trial , chemotherapy , leukemia , chronic lymphocytic leukemia